Takeda Pharmaceuticals U.S.A., Inc. history

1999: The firm and six other pharmaceutical concerns agree to pay $1.7 billion to settle a price-fixing class action suit.

During 2000, the firm's animal health businesses were consolidating into a new joint venture subsidiary, Takeda Schering-Plough Animal Health K.K.

During 2001, its pharmaceutical operations accounted for 75.5 percent of total sales.

In 2007, the United States Food and Drug Administration issued a “black box warning,” or “black label warning,” after studies had shown congestive heart failure as an increased risk from Actos treatment.

In November of 2010, after Takeda had acquired Millennium Pharmaceuticals, the company was forced to recall certain lots of the cancer medication Velcade from the United States, Japan, Malaysia and Europe after white particles were found to be present in vials.

In 2011, a study was released that claimed Actos may increase the risk of bladder cancer by as much as 40 percent and showed that the risk was more substantial for patients that were prescribed Actos for longer than a year.

By 2012, when Actos’ patent expired, thousands of lawsuits had been filed for injuries caused by the medication.

In February of 2013, the company was forced to recall all manufacturing lots of Omontys, a drug used to treat anemia which was jointly produced with Affymax, after 19 reports of anaphylaxis were reported in dialysis patients.

In 2014, Takeda agreed to settle about 9,000 lawsuits for $2.4 billion.

Takeda agreed to pay $2.4 billion to settle suits over cancer risk of Actos, New York Times (04/2015)

The cooperative agreement with the manufacturer Orexigen was dissolved after a clinical trial involving Contrave was badly conducted, costing $ Millions but leaving Takeda free of liability when the FDA added the medication to a watch list in April 2017.